The University of North Carolina (UNC) Global HIV Clinical Trials Unit (CTU) has a well established track record of high-quality, innovative clinical research, strong scientific leadership (both in and outside the NIH HIV/AIDS Networks), and access to critically important infected and at-risk populations in the Southeastern US and in Southern Africa. Drawn from a diverse team of clinical innvestigators spanning two continents, our CTU will be led by three experienced principal investigators (Joseph Eron MD, Jeffrey Stringer MD and Mina Hosseinipour MD) and will support all 5 NIH HIV Clinical Trials Networks: Adult Therapeutic Strategies, Strategies to Address HIV and HIV-associated Infections in Pediatric and Maternal Populations, Integrated HIV Prevention Strategies, Microbicide Strategies, and Vaccine Strategies to Prevent HIV Infection. The 5 Clinical Research Sites (CRS) will include Chapel Hill CRS led by David Wohl MD (Adult Therapeutic Strategies, Integrated Prevention, Microbicide and Vaccine), Raleigh CRS led by Kristine Patterson MD (Adult Therapeutic Strategies, Integrated Prevention, Vaccine), Greensboro CRS led by Cornelius Van Dam MD PhD (Adult Therapeutic Strategy and Integrated Prevention), Malawi CRS led by Francis Martinson MD PhD (all 5 Networks) and Zambia CRS led by Benjamin Chi MD (all 5 Networks). Supporting this leadership will be Network Science Teams, comprising global experts and site collaborators who will work to execute the network scientific agendas. The CTU has also assembled a diverse group of senior scientists and public health officials to serve on our Scientific and Strategic Advisory Group. The CTU administration incorporates a highly organized structure that will be responsive to our experienced research teams across the 5 sites and will provide ongoing evaluation to ensure optimal performance and efficiency. The CTU will be supported by state-of-the-art communications and has assembled outstanding laboratory, pharmacy, quality assurance, data management and regulatory support. With its robust administrative framework, the UNC Global HIV CTU will be uniquely positioned to provide scientific leadership and clinical trials infrastructure to advance the field of agenda of he NlAID networks.

Public Health Relevance

The NIH has established collaborative HIV/AIDS Clinical Trials Networks to advance the science of HIV prevention, care, and treatment. The UNC Global Clinical Trials Unit is eager to participate in this research, by reaching populations most affecte by the epidemic in North America and Africa and by contributing key scientific leadership to drive the research agenda.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
5UM1AI069423-10
Application #
8974222
Study Section
Special Emphasis Panel (ZAI1)
Program Officer
Adedeji, Bola
Project Start
2007-02-01
Project End
2020-11-30
Budget Start
2015-12-01
Budget End
2016-11-30
Support Year
10
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Ngongondo, McNeil; Miyahara, Sachiko; Hughes, Michael D et al. (2018) Hepatotoxicity During Isoniazid Preventive Therapy and Antiretroviral Therapy in People Living With HIV With Severe Immunosuppression: A Secondary Analysis of a Multi-Country Open-Label Randomized Controlled Clinical Trial. J Acquir Immune Defic Syndr 78:54-61
Torres, Thiago S; Harrison, Linda J; La Rosa, Alberto M et al. (2018) Quality of life improvement in resource-limited settings after one year of second-line antiretroviral therapy use among adult men and women. AIDS 32:583-593
Flynn, Patricia M; Taha, Taha E; Cababasay, Mae et al. (2018) Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomi J Acquir Immune Defic Syndr 77:383-392
Robertson, Kevin R; Jiang, Hongyu; Kumwenda, Johnstone et al. (2018) HIV Associated Neurocognitive Impairment in Diverse Resource Limited Settings. Clin Infect Dis :
Chernoff, Miriam C; Laughton, Barbara; Ratswana, Mmule et al. (2018) Validity of Neuropsychological Testing in Young African Children Affected by HIV. J Pediatr Infect Dis 13:185-201
Boivin, Michael J; Barlow-Mosha, Linda; Chernoff, Miriam C et al. (2018) Neuropsychological performance in African children with HIV enrolled in a multisite antiretroviral clinical trial. AIDS 32:189-204
Kalayjian, Robert C; Albert, Jeffrey M; Cremers, Serge et al. (2018) Women have enhanced bone loss associated with phosphaturia and CD4+ cell restoration during initial antiretroviral therapy. AIDS 32:2517-2524
Palumbo, Philip J; Fogel, Jessica M; Hudelson, Sarah E et al. (2018) HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. J Acquir Immune Defic Syndr 77:484-491
Rhodes, Scott D; Tanner, Amanda E; Mann-Jackson, Lilli et al. (2018) Community-Engaged Research as an Approach to Expedite Advances in HIV Prevention, Care, and Treatment: A Call to Action. AIDS Educ Prev 30:243-253
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912

Showing the most recent 10 out of 211 publications